Compare BAFN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | NYXH |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 137.5M |
| IPO Year | 2021 | 2021 |
| Metric | BAFN | NYXH |
|---|---|---|
| Price | $6.82 | $0.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 103.5K | ★ 202.7K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | N/A | $93.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $0.88 |
| 52 Week High | $9.80 | $5.92 |
| Indicator | BAFN | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 21.64 |
| Support Level | $5.98 | N/A |
| Resistance Level | $6.96 | $1.69 |
| Average True Range (ATR) | 0.62 | 0.06 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 58.04 | 3.07 |
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.